CALT - Calliditas Therapeutics AB Total Debt to Capital

This chart illustrates that the total debt-to-equity ratio for Calliditas Therapeutics (CALT) stands at 9.01. The Swedish developer of kidney therapies faces profitability threats due to its reliance on a single drug and ongoing patent disputes. The business is currently scaling sales under the management of a Japanese holding company, while its narrow specialization in rare pathologies provides the company with resilience across Western regions.

The high standards of Swedish management at Calliditas Therapeutics (CALT) within the nephrology segment are reflected in the current debt-to-equity ratio, confirming the strategic resilience of the business. This ratio, calculated as total liabilities divided by equity, determines the degree of financial leverage: low values minimize default risks, while moderate debt can accelerate the growth of return on assets.